{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-036492","form_type":"8-K","ticker":"VTGN","cik":"0001411685","company_name":"Vistagen Therapeutics, Inc.","filed_at":"2026-05-19T20:30:03+00:00","discovered_at":"2026-05-19T20:31:00.283703+00:00","generated_at":"2026-05-19T21:00:55.123015+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Vistagen appoints Angel S. Angelov, MD, MBA, as Chief Medical Officer effective May 18, 2026","bullets":["Dr. Angelov brings two decades of industry experience including roles at Karuna Therapeutics, Neurocrine Biosciences, Novartis, and Teva.","Annual base salary of $425,000, $50,000 signing bonus paid in two tranches, and eligibility for annual discretionary bonus (target 45% of salary).","Inducement grant of 150,000 stock options at $0.5955 per share, vesting over 4 years with 25% cliff at one year.","Dr. Angelov is board-certified in psychiatry and holds an MBA from Wharton; will lead clinical development for Vistagen's pherine pipeline."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-036492","json":"https://secwatch.observer/filing/0001628280-26-036492.json","markdown":"https://secwatch.observer/filing/0001628280-26-036492.md","text":"https://secwatch.observer/filing/0001628280-26-036492.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1411685/000162828026036492/0001628280-26-036492-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1411685/000162828026036492/vtgn-20260518.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-19T21:00:55.123015+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"44fefb9f34","claim":"Angel S. Angelov, M.D., MBA was appointed as Chief Medical Officer at Vistagen Therapeutics, Inc..","evidence_excerpt":"On May 18, 2026 (the “ Effective Date ”), Vistagen Therapeutics, Inc. (the “ Company ”) appointed Angel S. Angelov, M.D., MBA to serve as the Company’s Chief Medical Officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1411685/000162828026036492/0001628280-26-036492-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Medical Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}